These results support its potential use in treating cancers with high levels of ETB expression, such as melanoma, ovarian cancer, pancreatic cancer and triple-negative breast cancer, as determined in a recent clinical trial using the ENB-003 antagonist and the role of ETB in glioblastoma [41, 42]. This evidence concerns the gene EDNRB and triple-negative breast carcinoma.